Dambkowski Carl sold $730K of APGE
Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $132.74 ($0.73M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a single officer’s open-market transaction under a 10b5-1 plan; absent other news, it typically has limited fundamental impact.
Market read
Traders may note the insider sale for sentiment, but the filing alone does not introduce new business or financial fundamentals.
What to watch
The article provides no context on total insider holdings changes beyond the post-sale share count, and no link to performance or upcoming catalysts.
Background
This is an SEC Form 4 insider transaction disclosure for Apogee Therapeutics, Inc. (APGE).
Ticker impact
Apogee Therapeutics insider Form 4 shows CMO Carl Dambkowski sold 5,500 shares on 2026-07-01 for ~$730K under a 10b5-1 plan.
Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.
The filing is a disclosed open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/financial catalyst in the text.
Market effects
Minimal; this is company-specific insider transaction with no sector-wide read-across provided.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerApogee Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderCarl Dambkowski
Chief Medical Officer who sold 5,500 shares on 2026-07-01.
- trading mechanism10b5-1 plan
Pre-arranged plan cited as Yes, reducing interpretive weight of the sale.
